Dose-Dependent Modulation of Choroidal Neovascularization by Plasminogen Activator Inhibitor Type I: Implications for Clinical Trials — Vincent Lambert (2003) | RDL Network
These observations may help to reconcile reports with opposite results regarding the effects of PAI-1 on angiogenesis and certainly warn against uncontrolled use of PAI-1-modulating drugs in clinical trials.
Vincent Lambert, Carine Munaut, Agnès Noël, Françis Frankenne, Khalid Bajou, Robert D. Gerard, Peter Carmeliet, Marie Paule Defresne, Jean-Michel Foidart, Jean-Marie Rakic
Vincent Lambert, Carine Munaut, Agnès Noël, Françis Frankenne, Khalid Bajou, Robert D. Gerard, Peter Carmeliet, Marie Paule Defresne, Jean‐Michel Foidart, Jean‐Marie Rakic
Khalid Bajou, Véronique Masson, Robert D. Gerard, Petra M. Schmitt, Valérie Albert, Michael Praus, Leif R. Lund, Thomas Leth Frandsen, Nils Brünner, Keld Danø, Norbert E. Fusenig, Ulrich H. Weidle, Geert Carmeliet, David J. Loskutoff, D Collen, Peter Carmeliet, Jean‐Michel Foidart, Agnès Noël
Laetitia Devy, Silvia Blacher, Christine Grignet‐Debrus, Khalid Bajou, Véronique Masson, Robert D. Gerard, Ann Gils, Geert Carmeliet, Peter Carmeliet, Paul Declerck, Agnès Noël, Jean-Michel Foidart
Discussion(0)
No comments yet. Be the first to comment.